| Gene symbol | E7 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001526.4 (7604..7900) | dbXrefs | |
| Description | transforming protein E7 | ||||
| GTO ID | GTC2089 |
| Trial ID | NCT03912831 |
| Disease | Cancer |
| Altered gene | E7 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | KITE-439 |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers |
| Year | 2019 |
| Country | United States |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KT-US-478-0401|2020-005455-20 |
| Cohort 1 | |||||||||
|
|||||||||